Photo of Deepa Rangachari,  MD

Deepa Rangachari, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-1580
Fax: (617) 667-2518

Deepa Rangachari, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medicine, Hematology/Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Deepa Rangachari is a medical oncologist specializing in thoracic cancers. She is actively involved in clinical trials, with a particular interest in the management of patients with advanced/metastatic lung cancer and the application of targeted and immune therapies. She is additionally active in developing and evaluating innovative strategies in graduate and post-graduate medical education, with an emphasis on novel curricula in oncology. She serves as Associate Program Director for the BIDMC Hematology/Oncology Fellowship Program.

Publications

Powered by Harvard Catalyst
  • Carney BJ, Rangachari D, VanderLaan PA, Gowen K, Schrock AB, Ali SM, Costa DB. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. Lung Cancer 2017. PubMed
  • Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma. J Thorac Oncol 2017. PubMed
  • Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer 2016; 99:17-22. PubMed
  • Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer 2016. PubMed
  • Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship. J Cancer Educ 2016. PubMed
  • Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun 2017; 9:41-43. PubMed
  • Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 2016; 90:369-74. PubMed
  • Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2015. PubMed
  • Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer 2015. PubMed
  • Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015. PubMed
  • Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer 2015. PubMed
  • Rangachari D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol 2013; 14:580-94. PubMed
  • Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL, Meneshian A, Yang SC, Wolfgang CL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 2011; 15:1611-7. PubMed
  • Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun 2015; 4:174-181. PubMed
  • Rangachari D, Smith TJ. Integrating palliative care in oncology: the oncologist as a primary palliative care provider. Cancer J 2013; 19:373-8. PubMed
Hide